AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
CureVac Settles Patent Dispute with Pfizer and BioNTech for $500 Million, GSK to Receive 1% Royalties
ByAinvest
Friday, Aug 8, 2025 2:34 pm ET1min read
GSK is set to receive up to $500 million and 1% of royalties from future mRNA vaccine sales as part of a settlement between CureVac and Pfizer/BioNTech. The settlement comes as BioNTech completes its acquisition of CureVac. GSK will receive $370 million upfront and another $130 million on the closing of the acquisition. The settlement ends CureVac's litigation with Pfizer/BioNTech but does not affect GSK's ongoing litigation against them.
GSK (NYSE:GSK) is set to receive up to $500 million and 1% of royalties from future mRNA vaccine sales as part of a settlement between CureVac (NASDAQ:CVAC) and Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX). The settlement comes as BioNTech completes its acquisition of CureVac. GSK will receive $370 million upfront and another $130 million upon the closing of the acquisition [1].Under the terms of the agreement, CureVac and GSK will receive a total payment of $740 million, with GSK's share being $370 million upfront and $130 million on the closing of the acquisition. Additionally, GSK will receive single-digit royalties on future U.S. sales of COVID-19 vaccines developed by BioNTech and Pfizer [1].
The settlement ends CureVac's litigation with Pfizer and BioNTech but does not affect GSK's ongoing litigation against them. GSK's involvement in the case is complicated and unrelated to the separate litigation it has brought against Pfizer and BioNTech over similar infringement claims [2].
The resolution does not constitute an admission of liability with respect to any allegation raised by CureVac or GSK. BioNTech stressed that the settlement does not "in any way constitute an admission of liability with respect to any allegation raised by CureVac or GSK," noting that it "expressly denies" all such claims [2].
References:
[1] https://seekingalpha.com/news/4482370-gsk-curevac-settle-patent-dispute-with-pfizer-biontech
[2] https://www.fiercepharma.com/pharma/gsk-collects-320m-biontech-pfizer-settle-mrna-patent-spat-curevac
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet